Insilico Medicine (“Insilico”), a clinical-stage, generative AI-driven drug discovery company, today announced the nomination of ISM3830, a potential best-in-class, oral available, highly selective CBLB inhibitor with AI-empowered novel scaffold, as a preclinical candidate against multiple advanced tumors.  

A new study by researchers at Shinshu University highlights the essential role of gut microbiota in livestock health and productivity. The researchers show how probiotics, prebiotics, and synbiotics can safely enhance growth and immunity, and balance the growth of intestinal microbes, offering practical alternatives to antibiotics. As global restrictions on antibiotic use intensify, the findings support sustainable livestock management and contribute to reducing antimicrobial resistance risks.

Insilico Medicine (“Insilico”), a clinical-stage, generative AI-driven drug discovery company, today announced its participation in NeurIPS 2025, to be held in San Diego, USA, from December 2–7, 2025. Led by Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, and Petrina Kamya, PhD, Global Head of AI Platforms, Insilico’s experienced team will participate in the conference.

In a recent pioneering study, researchers at Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, harnessed its AI-driven generative chemistry platform, Chemistry42, to design a novel, first-in-class PROTAC targeting PKMYT1, D16-M1P2, which employs a dual mechanism of action—inducing PKMYT1 degradation while directly inhibiting its kinase activity. This innovative strategy holds promise for overcoming limitations of existing inhibitors, such as poor selectivity and acquired resistance, and to effectively target both the catalytic and non-catalytic functions of PKMYT1. As a result, the PROTAC demonstrates the potential for a more selective, potent, and durable therapeutic effect.

An international research team led by RMIT University have created tiny particles, known as nanodots, made from a metallic compound that can kill cancer cells while leaving healthy cells largely unharmed.

While this work is still at the cell-culture stage – it hasn’t been tested in animals or people – it points to a new strategy for designing cancer treatments that exploit cancer’s own weaknesses.

Using catalytic chemistry, researchers at Institute of Science Tokyo have achieved dynamic control of artificial membranes, enabling life-like membrane behavior. By employing an artificial metalloenzyme that performs a ring-closing metathesis reaction, the team induced the disappearance of phase-separated domains as well as membrane division in artificial membranes, imitating the dynamic behavior of natural biological membranes. This transformative research marks a milestone in synthetic cell technologies, paving the way for innovative therapeutic breakthroughs.

A study of data from seven outpatient facilities in the New York region found that 20-24% of all the breast cancers diagnosed during an 11-year period were found in women age 18 to 49, according to research being presented today at the annual meeting of the Radiological Society of North America (RSNA).